Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ProtheraCytes by CellProthera for Myocardial Infarction: Likelihood of Approval
ProtheraCytes is under clinical development by CellProthera and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II...